The frequency of occurrence of Hepatocellular Carcinoma after direct antiviral therapy in Hepatitis C virus patients

Abstract

Objective: To study the frequency of occurrence of hepatocellular carcinoma (HCC) in hepatitis C virus patients treated with direct acting antiviral (DAA) agents.
 Methods: This hospital based cross-sectional study was conducted in Mayo Hospital, Lahore from June, 2016 to January, 2018. Total 300 patients with HCV genotype 3, selected via Non-Probability Purposive Sampling technique, without prior or concurrent history of HCC, were given DAA agents and were followed up for 6 months after completion of therapy. Results were based on Quantitative PCR to assess Sustained Virological Response (SVR) and Ultrasound Abdomen to look for the appearance of any new lesion. Data was presented as mean±SD, frequency and percentages and was analyzed using SPSS Version 24.0.
 Results: Out of 300 patients, 179 (59.7%) were males and 121(40.3%) were females. Mean age of the patients was 55.08 ± 5.602 years. 214(71.3%) patients had compensated cirrhosis at the start of treatment and 86(28.7%) had decompensated cirrhosis. SVR was achieved in 200(93.4%) out of 214 patients with compensated cirrhosis and in 76(88.3%) out of 86 patients with decompensated cirrhosis. At six months post- treatment, 10(3.33%) patients developed HCC,2(0.7%) in the compensated group and 8(2.7%) in the decompensated group, out of which 5(6.6%) patients had achieved SVR.
 Conclusion: The frequency of HCC following DAA agents is significant (3.3%) even after achieving SVR. Caution must be exercised in prescribing DAA agents to HCV patients keeping this complication of HCC in mind.
 How to cite this:Aziz B, Nazar T, Akhlaq S. The frequency of occurrence of Hepatocellular Carcinoma after direct antiviral therapy in Hepatitis C virus patients. Pak J Med Sci. 2019;35(1):---------. doi: https://doi.org/10.12669/pjms.35.1.109
 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis

“…HCV infection is still a major cause of liver fibrosis, HCC, and liver failure [40] though patients with chronic hepatitis C are decreasing recently due to the fact that a number of promising new direct-acting antiviral agents (DAAs) have been developed in the past few years [41]. DM is closely associated with HCV-related outcomes mentioned above.…”

Predictors of Seroconversion of Hepatitis-C Virus in End-Stage Renal Disease Patients

“…In Pakistan, HCV infection is one of the most frequent diseases. It can result in Hepatocellular carcinoma and Decompensated Liver Disease 2,[11][12][13] . The risk of morbidity and mortality due to HCV is higher among patients with HD 14 .…”

New drugs and new concerns: Gaining insight through Pharmacovigilance of direct acting Anti-Viral’s in chronic HCV patients

“…22 Whereas, a local study has also provided data against the evident efficacy outcomes, suggesting that the Hepatocellular Carcinoma (HCC) was frequent among HCV patients treated with DAAs. 23 Limitations of the study: Although the study findings can be generalized to the whole population as it was multicenter including a large sample size but long-term follow-ups could enhance the knowledge regarding future implications of DAAs among the Pakistani population. Due to the design limitations, potential sources of bias can be information, sampling and interviewer bias and other limitation could be causality assessment of reported cases.…”